Angle PLC Announces Parsortix HER2 Assay Showcased at AACR 2024
PARSORTIX HER2 ASSAY SHOWCASED AT PRESTIGIOUS INTERNATIONAL CANCER CONFERENCECTC HER2 assay being developed for HER2 targeted drugs and antibody drug...
Month: April 2024
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Toronto, Ontario--(Newsfile Corp. - April 7, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
SHANGHAI, China, April 07, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically...
American College of Osteopathic Family Physicians Conclave of Fellows Welcomes 2024 Class
CHICAGO, IL / ACCESSWIRE / April 5, 2024 / The American College of Osteopathic Family Physicians (ACOFP) Conclave of Fellows...
Defence Therapeutics Announces Warrant Terms Amendment
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Tidepool Achieves SOC 2 Type II Compliance
PALO ALTO, Calif.--(BUSINESS WIRE)--#DiabetesData--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the achievement of...
Pathways Hospice Names Dr. Nathaniel Chappelle, M.D. as Medical Director
FORT COLLINS, CO / ACCESSWIRE / April 5, 2024 / Pathways Hospice recently named Dr. Nathaniel Chappelle as Medical Director...
United States Clinical Oncology Next Generation Sequencing Market Research Report 2023-2028: Data Analysis and Interpretation Tools to Streamline Processes and Growth in Genomic Medicine – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Clinical Oncology Next Generation Sequencing Market, By Region, By Competition Forecast & Opportunities, 2018-2028F" report has...
All Care Therapies Expands Pediatric Services With Acquisition of Therapy Blocks
LAS VEGAS, NV / ACCESSWIRE / April 5, 2024 / All Care Therapies, a leading provider of speech, occupational, and...
StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
TORONTO, ON / ACCESSWIRE / April 5, 2024 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated...
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Planet 13 Announces Grand Opening Date for DAZED! Lounge at the World’s Largest Dispensary – Designed to Elevate the Cannabis Consumption Experience
LAS VEGAS, NV / ACCESSWIRE / April 5, 2024 / Planet 13 Holdings Inc. (CSE:PLTH)(OTCQX:PLNH) ("Planet 13" or the "Company"),...
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilitiesTORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc....
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic...
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
Anticipated net proceeds, along with existing cash and cash equivalents, expected to extend cash runway into 2026NEW YORK, April 05,...
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
New development pathway significantly expands addressable patient population for IV Choline ChlorideIV Choline Chloride has the potential to become the...
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
PITTSBURGH, April 05, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage...